Search

Your search keyword '"Mutz, Antonius"' showing total 6 results
Start Over Author "Mutz, Antonius"
6 results on '"Mutz, Antonius"'

2. Cytochrome P450 2B6 (CYP2B6) and constitutive androstane receptor (CAR) polymorphisms are associated with early discontinuation of efavirenz-containing regimens

Author

Wyen, Christoph, Hendra, Heidy, Siccardi, Marco, Platten, Martin, Jaeger, Hans, Harrer, Thomas, Esser, Stefan, Bogner, Johannes R., Brockmeyer, Norbert H., Bieniek, Bernhard, Rockstroh, Juergen, Hoffmann, Christian, Stoehr, Albrecht, Michalik, Claudia, Dlugay, Verena, Jetter, Alexander, Knechten, Heribert, Klinker, Hartwig, Skaletz-Rorowski, Adriane, Fätkenheuer, Gerd, Egan, Deirdre, Back, David J., Owen, Andrew, Dupke, Stephan, Carganico, Andreas, Baumgarten, Axel, Koeppe, Siegfried, Kreckel, Peter, Lauenroth-Mai, Elke, Schlote, Frank, Schuler, Christoph, Freiwald, Matthias, Rausch, Michael, Gölz, Jörg, Moll, Arend, Zeitz, Martin, Brockmeyer, Norbert, Hower, Martin, Reuter, Stefan, Harrer, Thomas, Esser, Stefan, Staszewski, Schlomo, Plettenberg, Andreas, Fenske, Stefan, Buhk, Thomas, Stellbrink, Hans-Jürgen, Schmidt, Reinhold, Kuhlmann, Birger, Mosthaf, Franz, Rieke, Ansgar, Scholten, Stefan, Jaeger, Hans, Jaegel-Guedes, Eva, Volkert, Ramona, Becker, Werner, Hartl, Helmut, Mutz, Antonius, Ulmer, Albrecht, Frietsch, Bernhard, and Müller, Markus

Published
2011
Full Text
View/download PDF

3. Cytochrome P450 2B6 (CYP2B6) and constitutive androstane receptor (CAR) polymorphisms are associated with early discontinuation of efavirenz-containing regimens

Author

Wyen, Christoph, Hendra, Heidy, Siccardi, Marco, Platten, Martin, Jaeger, Hans, Harrer, Thomas, Esser, Stefan, Bogner, Johannes R., Brockmeyer, Norbert H., Bieniek, Bernhard, Rockstroh, Juergen, Hoffmann, Christian, Stoehr, Albrecht, Michalik, Claudia, Dlugay, Verena, Jetter, Alexander, Knechten, Heribert, Klinker, Hartwig, Skaletz-Rorowski, Adriane, Fätkenheuer, Gerd, Egan, Deirdre, Back, David J., Owen, Andrew, Dupke, Stephan, Carganico, Andreas, Baumgarten, Axel, Koeppe, Siegfried, Kreckel, Peter, Lauenroth-Mai, Elke, Schlote, Frank, Schuler, Christoph, Freiwald, Matthias, Rausch, Michael, Gölz, Jörg, Moll, Arend, Zeitz, Martin, Brockmeyer, Norbert, Hower, Martin, Reuter, Stefan, Staszewski, Schlomo, Plettenberg, Andreas, Fenske, Stefan, Buhk, Thomas, Stellbrink, Hans-Jürgen, Schmidt, Reinhold, Kuhlmann, Birger, Mosthaf, Franz, Rieke, Ansgar, Scholten, Stefan, Jaegel-Guedes, Eva, Volkert, Ramona, Becker, Werner, Hartl, Helmut, Mutz, Antonius, Ulmer, Albrecht, Frietsch, Bernhard, and Müller, Markus

Abstract

Objectives Cytochrome P450 2B6 (CYP2B6) is responsible for the metabolic clearance of efavirenz and single nucleotide polymorphisms (SNPs) in the CYP2B6 gene are associated with efavirenz pharmacokinetics. Since the constitutive androstane receptor (CAR) and the pregnane X receptor (PXR) correlate with CYP2B6 in liver, and a CAR polymorphism (rs2307424) and smoking correlate with efavirenz plasma concentrations, we investigated their association with early (

Published
2017

5. Pegylated interferon alpha-2b plus ribavirin for the treatment of chronic hepatitis C in HIV-coinfected patients.

Author

Voigt, Esther, Schulz, Christian, Klausen, Gerd, Goelz, Joerg, Mauss, Stefan, Schmutz, Guenther, Jessen, Heiko, Weitner, Lutwin, Mutz, Antonius, Schranz, Dietmar, Rockstroh, Juergen K, and Kaad Study Group

Subjects
THERAPEUTIC use of proteins, HIV infection complications, ANTIVIRAL agents, COMBINATION drug therapy, CLINICAL trials, COMPARATIVE studies, RESEARCH methodology, MEDICAL cooperation, POLYETHYLENE glycol, PROTEINS, RECOMBINANT proteins, RESEARCH, EVALUATION research, RIBAVIRIN, TREATMENT effectiveness, CHRONIC hepatitis C, DISEASE complications
Abstract

Objectives: HIV-coinfection accelerates the course of HCV-related liver disease. Since, highly active anti-retroviral therapy significantly improved survival of HIV-patients more coinfected patients develop end stage liver disease. Therefore, treatment options for chronic hepatitis C in HIV-coinfected patients need to be evaluated.Methods: Efficacy and safety of pegylated interferon alpha-2b (peg IFN) plus ribavirin (RBV) was examined within this prospective, uncontrolled, multicentre trial. Patients received peg IFN (1.5 microg/kg) once weekly plus RBV 800 mg daily for 48 weeks for HCV genotypes (GT) 1/4 and 24 weeks for GT 2/3.Results: One hundred and twenty-two patients were enrolled. Patients were predominantly male (68%) and former i.v. drug users (61%). Baseline characteristics (median) were as follows: age 39 years (range 23-58), CD4 count 494 cells/microl (range 150-1578/microl), HIV-RNA 2.3log copies/ml (range <1.7-5.4log copies/ml). 61% currently received anti-retroviral treatment. Fifty-six percent had HCV GT 1. EOT response was achieved by 52%. However, only 25% achieved sustained response (SR) due to a high relapse rate. SR rates were significantly higher among patients with GT 2/3 compared to those with GT 1/4 (44 vs. 18%). SR was observed in only one patient without early response (ER). Discontinuation rate was 30%, 21% discontinued due to adverse events.Conclusion: Peg IFN/RBV appears safe and effective in HIV/HCV-coinfected patients. GT 2/3 is associated with better SR. Lack of ER strongly predicts non-response. High relapse rates substantially reduce treatment success. In terms of toxicity neuro-psychiatric side effects frequently required treatment discontinuation. [ABSTRACT FROM AUTHOR]

Published
2006
Full Text
View/download PDF

6. Cytochrome P450 2B6 (CYP2B6) and constitutive androstane receptor (CAR) polymorphisms are associated with early discontinuation of efavirenz-containing regimens

Author

Wyen, Christoph, Hendra, Heidy, Siccardi, Marco, Platten, Martin, Jaeger, Hans, Harrer, Thomas, Esser, Stefan, Bogner, Johannes R., Brockmeyer, Norbert H., Bieniek, Bernhard, Rockstroh, Juergen, Hoffmann, Christian, Stoehr, Albrecht, Michalik, Claudia, Dlugay, Verena, Jetter, Alexander, Knechten, Heribert, Klinker, Hartwig, Skaletz-Rorowski, Adriane, Fätkenheuer, Gerd, Egan, Deirdre, Back, David J., Owen, Andrew, Dupke, Stephan, Carganico, Andreas, Baumgarten, Axel, Koeppe, Siegfried, Kreckel, Peter, Lauenroth-Mai, Elke, Schlote, Frank, Schuler, Christoph, Freiwald, Matthias, Rausch, Michael, Gölz, Jörg, Moll, Arend, Zeitz, Martin, Brockmeyer, Norbert, Hower, Martin, Reuter, Stefan, Staszewski, Schlomo, Plettenberg, Andreas, Fenske, Stefan, Buhk, Thomas, Stellbrink, Hans-Jürgen, Schmidt, Reinhold, Kuhlmann, Birger, Mosthaf, Franz, Rieke, Ansgar, Scholten, Stefan, Jaegel-Guedes, Eva, Volkert, Ramona, Becker, Werner, Hartl, Helmut, Mutz, Antonius, Ulmer, Albrecht, Frietsch, Bernhard, Müller, Markus, Wyen, Christoph, Hendra, Heidy, Siccardi, Marco, Platten, Martin, Jaeger, Hans, Harrer, Thomas, Esser, Stefan, Bogner, Johannes R., Brockmeyer, Norbert H., Bieniek, Bernhard, Rockstroh, Juergen, Hoffmann, Christian, Stoehr, Albrecht, Michalik, Claudia, Dlugay, Verena, Jetter, Alexander, Knechten, Heribert, Klinker, Hartwig, Skaletz-Rorowski, Adriane, Fätkenheuer, Gerd, Egan, Deirdre, Back, David J., Owen, Andrew, Dupke, Stephan, Carganico, Andreas, Baumgarten, Axel, Koeppe, Siegfried, Kreckel, Peter, Lauenroth-Mai, Elke, Schlote, Frank, Schuler, Christoph, Freiwald, Matthias, Rausch, Michael, Gölz, Jörg, Moll, Arend, Zeitz, Martin, Brockmeyer, Norbert, Hower, Martin, Reuter, Stefan, Staszewski, Schlomo, Plettenberg, Andreas, Fenske, Stefan, Buhk, Thomas, Stellbrink, Hans-Jürgen, Schmidt, Reinhold, Kuhlmann, Birger, Mosthaf, Franz, Rieke, Ansgar, Scholten, Stefan, Jaegel-Guedes, Eva, Volkert, Ramona, Becker, Werner, Hartl, Helmut, Mutz, Antonius, Ulmer, Albrecht, Frietsch, Bernhard, and Müller, Markus

Abstract

Objectives Cytochrome P450 2B6 (CYP2B6) is responsible for the metabolic clearance of efavirenz and single nucleotide polymorphisms (SNPs) in the CYP2B6 gene are associated with efavirenz pharmacokinetics. Since the constitutive androstane receptor (CAR) and the pregnane X receptor (PXR) correlate with CYP2B6 in liver, and a CAR polymorphism (rs2307424) and smoking correlate with efavirenz plasma concentrations, we investigated their association with early (<3 months) discontinuation of efavirenz therapy. Methods Three hundred and seventy-three patients initiating therapy with an efavirenz-based regimen were included (278 white patients and 95 black patients; 293 male). DNA was extracted from whole blood and genotyping for CYP2B6 (516G → T, rs3745274), CAR (540C → T, rs2307424) and PXR (44477T → C, rs1523130; 63396C → T, rs2472677; and 69789A → G, rs763645) was conducted. Binary logistic regression using the backwards method was employed to assess the influence of SNPs and demographics on early discontinuation. Results Of the 373 patients, 131 withdrew from therapy within the first 3 months. Black ethnicity [odds ratio (OR) = 0.27; P = 0.0001], CYP2B6 516TT (OR = 2.81; P = 0.006), CAR rs2307424 CC (OR = 1.92; P = 0.007) and smoking status (OR = 0.45; P = 0.002) were associated with discontinuation within 3 months. Conclusions These data indicate that genetic variability in CYP2B6 and CAR contributes to early treatment discontinuation for efavirenz-based antiretroviral regimens. Further studies are now required to define the clinical utility of these associations

Catalog

Books, media, physical & digital resources
See catalog results